To date, Proteologics Inc, USA has raised about 33$ million from investors including Concord Ventures (Israel), Aurum Ventures MKI Ltd (Israel), Giza Fund (Israel), The Challenge Fund (Etgar - Israel) and Teva Pharmaceutical Industries Ltd.

On March 2010 Proteologics ltd, an Israeli subsidiary of Proteologics Inc completed Initial public offering ("IPO") on the Tel Aviv Stock Exchange ("TASE"). Proteologics ltd successful IPO on TASE fulfilled the last closing condition that triggered a private equity investment of 2.5M USD in the company by GlaxoSmithKline LLC ("GSK") - one of the world leading pharmaceutical companies.

Investors:

GlaxoSmithKline (GSK)

Teva Pharmaceutical Industries Ltd.

Aurum Ventures MKI

Giza Venture Fund

The Challenge Fund

Concord Ventures